CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
Benoit YouPatrick RobelinMichel TodChristophe LouvetJean-Pierre LotzSophie Abadie-LacourtoisieMichel FabbroChristophe DesauwNathalie Bonichon-LamichhaneJean-Emmanuel KurtzPhilippe FollanaMarianne LeheurteurFrancesco Del PianoGwenaël FerronGaëtan De RauglaudreIsabelle Ray-CoquardPierre CombeAnnick Chevalier-PlaceFlorence JolyAlexandra LearyEric Pujade-LauraineGilles FreyerOlivier ColombanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The tumor-primary chemosensitivity, assessed by the modeled CA-125 KELIM calculated during neoadjuvant chemotherapy (http://www.biomarker-kinetics.org/CA-125-neo), may be a major parameter to consider for decision-making regarding IDS attempt, and selecting patients for treatments meant to reverse the primary chemoresistance.See related commentary by May and Oza, p. 4432.
Keyphrases
- phase ii
- neoadjuvant chemotherapy
- clinical trial
- open label
- decision making
- end stage renal disease
- phase iii
- locally advanced
- newly diagnosed
- ejection fraction
- chronic kidney disease
- protein kinase
- lymph node
- sentinel lymph node
- prognostic factors
- squamous cell carcinoma
- study protocol
- radiation therapy
- randomized controlled trial
- double blind
- early stage
- cancer stem cells